Skip to main content
Clinical Trials/NCT05371600
NCT05371600
Completed
Phase 4

The Effect of Preoperative Anxiolysis With Intravenous Midazolam on Intraoperative Sevoflurane Gas Consumption: A Prospective Randomized Controlled Study

Cukurova University1 site in 1 country80 target enrollmentDecember 2, 2022

Overview

Phase
Phase 4
Intervention
Midazolam
Conditions
Midazolam
Sponsor
Cukurova University
Enrollment
80
Locations
1
Primary Endpoint
Sevoflurane consumption
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This prospective, randomized, double-blind, placebo-controlled study is performed after obtaining written informed consent of patients who are scheduled for elective general surgery. After the admission to the preoperative unit 30 minutes before the surgery, The preoperative anxiety of patients is evaluated by The State-Trait Anxiety Inventory (STAI). Patients are randomly assigned to one of two groups in a 1:1 ratio by a computer-generated list. Patients receive midazolam IV at 0.04 mg/kg (group M) and an equal volume of saline IV (group C, control group). Anesthesia is induced with 2mg/kg of IV propofol. At a dose of 0.6 mg/kg, IV rocuronium bromide is given for neuromuscular blockade. Anesthesia is maintained at 2% sevoflurane. At the end of the surgery, anesthesia is terminated and the awake patients are extubated.

Detailed Description

An equal depth of anesthesia is achieved by evaluating an entropy value of 40-50 during the operation. Heart rate, blood pressure, the amount of sevoflurane consumed (ml), end-tidal sevoflurane concentration (%), sevoflurane MAC, inspiratory sevoflurane (%) are recorded at baseline and 15-minute intervals.

Registry
clinicaltrials.gov
Start Date
December 2, 2022
End Date
April 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ersel GULEC

Principal Investigator

Cukurova University

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists physical status 1 and 2
  • patients who are scheduled for elective surgery

Exclusion Criteria

  • history of psychiatric disease
  • use of psychotropic medications
  • neurological disorders
  • chronic pain
  • cardiovascular, respiratory, and hepatic diseases.

Arms & Interventions

Group M

Patients receive midazolam IV at 0.04 mg/kg (group M).

Intervention: Midazolam

Group C

Patients receive an equal volume of saline IV (group C, control group).

Intervention: Saline

Outcomes

Primary Outcomes

Sevoflurane consumption

Time Frame: 1 hour

The amount of sevoflurane consumed (ml)

Secondary Outcomes

  • end-tidal sevoflurane concentration (%)(1 hour)

Study Sites (1)

Loading locations...

Similar Trials